Alnylam Faces Challenges at Key Cardiology Conference
By Editor • August 27, 2026 • 1 min read
The upcoming European Society of Cardiology Congress in Munich poses significant challenges for Alnylam Pharmaceuticals. The company is grappling with uncertainty surrounding its ATTR-CM drugs following the unexpected failure of a rival treatment.
AstraZeneca and Ionis Pharmaceuticals will share insights on why their drug, eplontersen, did not show a meaningful reduction in cardiovascular risks.
Source: www.statnews.com
#Alnylam #AstraZeneca #cardiology #eplontersen #ESC Congress
